Entries by Thomas Gabrielczyk

LIfT BioSciences Ltd receives €12m for clinical translation of IMANs

LIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory Alpha Neutrophils (IMANs). This funding will enable the preparation of the world’s first allogeneic therapy using synthetically programmed neutrophil granulocytes for Phase I trials.

Import tariff of 15%: significant implications for pharmaceutical firms

In the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the imposition of the same rate on EU investments exceeding US$600m in the US, without formal resistance. Industry associations have reacted with strong criticism.

Abivax soars 500% on TOP-Line data

In a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.